Results 201 to 210 of about 5,782,005 (384)

SIX BALB/c IgA MYELOMA PROTEINS THAT BIND ß-(1 → 6)-D-GALACTAN [PDF]

, 1973
Stuart Rudikoff, Elizabeth B. Mushinski, Michael Potter, C.P.J. Glaudemans, Michael E. Jolley   +4 more
openalex   +1 more source

Reduction in C‐reactive protein indicates successful targeting of the IL‐1/IL‐6 axis resulting in improved survival in early stage multiple myeloma

American journal of hematology/oncology, 2016
J. Lust, M. Lacy, S. Zeldenrust, T. Witzig, Laurie L. Moon-Tasson, C. Dinarello, K. Donovan   +6 more
semanticscholar   +1 more source

Emerging Target Discovery Strategies Drive the Decoding of Therapeutic Power of Natural Products and Further Drug Development: A Case Study of Celastrol

Exploration, EarlyView.
Using celastrol as a case study, this review summarizes various target discovery strategies for natural products, including chemical proteomics, protein microarray, degradation‐based protein profiling, proteome‐wide label‐free approaches, network pharmacology, target‐based drug screening, and indirect strategies.
Yanbei Tu, Guiyu Dai, Yanyan Chen, Lihua Tan, Hanqing Liu, Meiwan Chen   +5 more
wiley   +1 more source

Binding of IgE Myeloma Proteins to Human Cultured Lymphoblastoid Cells [PDF]

, 1976
A González-Molina, Hans L. Spiegelberg
openalex   +1 more source

Mechanisms of action and clinical development of elotuzumab [PDF]

, 2017
Colonna, Marco, Ritchie, David
core   +2 more sources

Targeting the Menin–KMT2A interaction in leukemia: Lessons learned and future directions

International Journal of Cancer, EarlyView.
Abstract Chromosomal rearrangements involving the Mixed Lineage Leukemia gene (MLL1, KMT2A) are defining a genetically distinct subset in about 10% of human acute leukemias. Translocations involving the KMT2A‐locus at chromosome 11q23 are resulting in the formation of a chimeric oncogene, where the N‐terminal part of KMT2A is fused to a variety of ...
Florian Perner, Jayant Y. Gadrey, Scott A. Armstrong, Michael W. M. Kühn   +3 more
wiley   +1 more source

C-reactive protein promotes bone destruction in human myeloma through the CD32–p38 MAPK–Twist axis

Science Signaling, 2017
Jing Yang, Zhiqiang Liu, Huan Liu, Jin He, J. Yang, P. Lin, Qiang Wang, J. Du, Wencai Ma, Zheng Yin, E. Davis, R. Orlowski, J. Hou, Q. Yi   +13 more
semanticscholar   +1 more source

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, EarlyView.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source

The interaction between protein A and immunoglobulin G as studied with the Fc‐fragment of a myeloma protein by circular dichroism [PDF]

, 1975
Ingvar Sjöholm
openalex   +1 more source

Deregulated enhancer‐promoter communication in cancer through altered nuclear architecture

International Journal of Cancer, EarlyView.
Abstract Enhancers are critical regulators of gene expression. Structural variations in cancer genomes can lead to enhancer hijacking, where oncogenes are activated by mistargeted enhancer activity. Novel enhancer‐promoter interactions may also arise through chromosomal rearrangements that create extrachromosomal DNA elements.
Isabelle Seufert, Claire Vargas, Sina Jasmin Wille, Karsten Rippe   +3 more
wiley   +1 more source